Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Optimising AHF Treatment to Relieve Symptoms
Author(s): Alexandre Mebazaa Added: 7 years ago
In this video, Prof Alexandre Mebazaa (University Paris 7, FR)looks at the optimisation strategies used to treat acute heart failure (AHF). His presentationaims to highlight that: Acute heart failure involves both leftand right-sided ventricular failure Symptomatic relief may not correlate with improved outcomes Acute heart failure can affect other organs such as the kidneys and liver Pre… View more

Heart Failure
Symptoms Organ Injury in Acute Heart Failure Treatment - ESC ACCA 2016
Author(s): João Morais Added: 7 years ago
Biography João Morais is Chief of the Cardiology Division and Chairman of the Clinical Research Centre of Leiria Hospital, Portugal. He is Past-Chair of the ESC Working Group on Thrombosis, member of the scientific committee of ESC congress (2014-2018) and also of ACCA (2014-2016) and has been a member of several task forces throughout his career [Stable Angina (2006); Antiplatelets (2011 and… View more

Heart Failure
The PRESERVED-HF Study
Author(s): Mikhail Kosiborod Added: 2 years ago
In this short presentation onbehalf of the investigators,Dr Mikhail Kosiborod (St Luke’s Mid America Heart Institute), summarises the PRESERVED-HF study. HFpEFisstillthebiggestunmet need in heart failurepractice. Whilst SGLT-2 inhibitorshave showedpromisingeffectsinHFpEFpatients in someof the largediabetes CVOTs,1,2until the publication of EMPEROR-PRESERVED3no agent… View more

Heart Failure
ACC 22: Results From the EMPULSE Study
Author(s): Mikhail Kosiborod Added: 2 years ago
In this short interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) summarises the main findings of the EMPULSE study, originally presented as a late-breaking trial at ACC.22(NCT04157751). The study investigated the effects of empagliflozin on symptoms,physical limitations and quality of life inacute heart failure. The trial demonstrated that treatment with empagliflozin… View more

Heart Failure
Author(s): Lampros Papadimitriou , Charles K Moore , Javed Butler , et al Added: 4 years ago
Heart failure (HF) is a global epidemic which affects about 6 million adults in the US. It is projected that by 2030 the total cost of HF will reach US$70 billion. Despite the development of novel drugs and devices, the mortality burden of HF remains high, with one in three patients dying within 1 year of hospitalisation for HF and 40–50% within 5 years of diagnosis.1 Patients with HF are… View more

Standards & Guidelines

Heart Failure
Author(s): Lisa LeMond , Sarah J Goodlin Added: 3 years ago
In the infancy of the hospice and palliative care movements, Dame Cicely Saunders noted that terminally ill patients and their families were often told “there is nothing more to do.” Her unwavering belief was that those words betrayed the patient, and that “there is so much more to do.”1 Stage D heart failure (HF) is defined as HF in which refractory symptoms persist despite guideline-directed… View more

Standards & Guidelines

Heart Failure
HFA 23: Diagnosis in Heart Failure in Women
Author(s): John GF Cleland Added: 10 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database. Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men. … View more

Demographic

Heart Failure
Redwood-HCM: Second-Generation Drug for HCM Well-Tolerated by Patients
Author(s): Martin S Maron Added: 2 years ago
In this video, Dr Martin Maron (Tufts Medical Center, Boston, MA, US) discusses the findings of Redwood-HCM, a phase 2 dose-escalation clinical trial evaluating the effect of second-gen drug aficamten in the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). This research was originally presented at HFSA 2021. Results indicate aficamten was well tolerated and resulted in… View more

Heart Failure
The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion
Author(s): Mikhail Kosiborod , Dalane W Kitzman Added: 2 years ago
In this series, on behalf of the investigators, Dr Mikhail Kosiborod (St Luke’s Mid America Heart Institute, Kansas City, US) and Dr Dalane Kitzman (Wake Forest School of Medicine, North Carolina, US) address the PRESERVED-HF study. In the first part of the programme, Dr Mikhail Kosiborod provides a comprehensive overview of the study, summarising the challenge of heart failure with… View more

Heart Failure
Author(s): Amam Mbakwem , Francis Aina , Casmir Amadi Added: 3 years ago
The prevalence of major depression in chronic heart failure (HF) is about 20–40 %, which is 4–5 % higher than in the normal population.1–3 Depression in heart failure has become a major issue as the burden of heart failure has continued to increase, and many studies have suggested poorer outcomes in HF patients reporting depression.4–8 The cost of managing HF has continued to escalate, and high… View more

Heart Failure

Prevention & Chronic Conditions